Section I: IDENTIFICATION OF SUBSTANCE AND SOCIETY

1.1. Identification of the substance

Product form:. Solution for injection
Product name: Anticholium®
Active substance : Physostigmine salicylate.
Chemical name : [(3aR,8bS)-3,4,8b-trimethyl-2,3a-dihydro-1H-pyrrolo[2,3-b]indol-7-yl] N-methylcarbamate;2-hydroxybenzoic acid
National Drug Code (NDC): 81284-831-05
Molecular formula: Physostigmine salicylate : $C_{15}H_{21}N_3O_2 \bullet C_7H_6O_3$.

1.2. Uses

As an antidote or antagonist in cases of poisoning or overdose
For professional use only

1.3. Information about the security data sheet provider

Company	Distributor
Provepharm SAS 22 Rue Marc Donadille 13013 Marseille, France Phones: 04 91 08 69 30 Website: www.provepharm.com Email: hse@provepharm.com	**Provepharm Inc.** 100 Springhouse drive, Suite 105, Collegeville, PA 19426, USA Phone: +1 610 601 8600

1.4. Emergency telephone number:

CHEMTREC: 1-800-424-9300 (within USA and Canada), +1 703-527-3887 (outside USA and Canada).

Section 2: HAZARDS IDENTIFICATION

2.1. Potential health hazards

Carcinogenicity : Not available
Mutagenicity : Not available
Teratogenicity : Not available
Developmental toxicity : Not available

May cause irritation of the eyes, skin, gastrointestinal and respiratory tract.
For side effects see Information for use.

2.2. Other hazards

Health Effects: Due to the sodium metabisulfite content, hypersensitivity reactions may occur in isolatedcases, especially in asthmatics, which can manifest as retching, diarrhoea, wheezing, acute asthma attack, impaired consciousness or shock. These reactions can vary greatly between individuals and can also lead to life-threatening conditions. Under such conditions, a benefit-risk assessment is required when using ANTICHOLIUM® as an antidote in poisoning and a cortisone preparation must be readily available. Acute cardiac arrest is possible during treatment with tricyclic antidepressants, therefore continuous monitoring of the ECG is required when Anticholium is used as an antidote in this indication.

Section 3: COMPOSITION/INFORMATIONS ON THE SUBSTANCE

3.1. Substances

Not applicable

3.2. Mixtures

Name	Product identifier	Quantity/mL	Classification
Physostigmine salicylate	CAS-No.: 57-64-7 Molecular weight: 413.5 g/mol EC number: 200-343-8	2.0 mg/5 mL (0.4 mg in 1 mL)	Acute Tox. 1, H300 Acute Tox. 2, H330 
Sodium metabisulfite	CAS-No.: 7681-57-4 Molecular weight: 190.11 g/mol EC number: 231-673-0	2.5 mg/5 mL (equivalent to: 1.68 mg SO2)	Acute Tox. 4, H302 Eye Dam. 1, H318 
Sodium edetate		-	Acute Tox. 4, H332 STOT RE 2, H373 
Water for injection	CAS-No.: 7732-18-5	-	Not listed

Full text of hazard classes and H-statements: see section 16.

SECTION 4: FIRST AID MEASURES

4.1. Description of first aid measures

After inhalation: If inhaled, remove to fresh air. Seek medical attention immediately.
After skin contact: In case of contact, immediately wash skin with plenty of water and soap or mild detergent for at least 15 minutes. Remove contaminated clothing and shoes. Wash clothes and thoroughly clean shoes before reuse. Seek medical attention immediately.
After eye contact: Check for and remove any contacts lenses. Immediately flush eyes with plenty of water or normal saline solution for at least 15 minutes. Seek medical attention immediately.
After ingestion: Wash out mouth with water and administer fresh water if the person is conscious. Do not induce vomiting unless directed to do so by a medical professional. Never give anything by mouth to an unconscious person. Loosen tight clothing such as tie, collar and/or belt. Seek medical attention immediately.

SECTION 5: FIREFIGHTING MEASURES

5.1. Extinguishing media

Suitable extinguishing media: Use water spray, dry chemical, fog or foam.
Unsuitable extinguishing media: Not known.

5.2. Special hazards arising from the substance or mixture

Combustion Products: When heated to decomposition, it emits toxic fumes of nitrogen oxides.

SECTION 6: ACCIDENTAL RELEASE MEASURES

6.1. Personal precautions, protective equipment and emergency procedures

General Measures: Use personal protective equipment recommended in Section 8 of this document and isolate the hazard area.

6.1.1. For Non-emergency Personnel
Protective Equipment: Use appropriate personal protection equipment (PPE) as identified in section 8.
Emergency Procedures: Evacuate unnecessary personnel.
6.1.2. For Emergency Responders
Protective Equipment: Equip cleanup crew with proper protection. Refer to section 8: Exposure controls/personal protection.
Emergency Procedures: Isolate the hazard area. Ventilate area.

6.2. Environmental precautions
Avoid dispersal of spilled material and runoff and contact with soil, waterways, drains and sewers

6.3. Material for containment and cleaning up
Soak up with inert absorbent material and dispose as hospital waste. Wipe working area surfaces to dryness, and then wash with soap and water.
For proper waste disposal, see section 13 of the SDS.

SECTION 7: HANDLING AND STORAGE

7.1. Precautions for safe handling
Recommendations for handling: Avoid exposure to light, air, moisture and excessive heat.
Handle in a well-ventilated place.
Avoid contact with incompatible materials.
Wear suitable Personal Protection Equipment (see section 8).
Keep the substance/mixture away from drains, surface or ground waters.

Recommendations for personal hygiene: Do not eat, drink and smoke in the working areas.
Wash hands after handling the substance/mixture.
Remove contaminated clothing and protective equipment.

7.2. Conditions for safe storage, including any incompatibilities
Storage: Do not expose to heat sources or high temperature.
Keep container tightly closed. Keep container in a cool. Store not above 25°C. (77°F).
Do not expose to sunlight. Store in the outer packaging.
In the intact container: 3 years
The solution for infusion must be used immediately after preparation.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the carton or label after “EXP”. The expiry date refers to the last day of that month

SECTION 8: EXPOSURE CONTROLS/PERSONAL PROTECTION

8.1. Control parameters
Exposure limit: Not available.

8.2. Exposure controls
Appropriate engineering controls: Handle in accordance with good clinical hygiene and safety practice. Wash hands before breaks and at the end of the day.
Hand protection: Handle with gloves (Nitrile rubber). Gloves must be inspected prior to use. Use proper glove removal technique (without touching glove's outer surface) to avoid skin contact with this product. Dispose of contaminated gloves after use in accordance with applicable laws and good laboratory practices. Wash and dry hands. (in accordance with EN374, ASTM F1001 or international equivalent).
Eye protection: Wear safety glasses or goggles if eye contact is possible (in accordance with EN166, ANSI Z87.1 or international equivalent).
Skin and body protection: Wear suitable working clothes.
Respiratory protection: Not required
Control of environmental exposure: Do not let product enter drains.

SECTION 9: PHYSICAL AND CHEMICAL PROPERTIES

9.1. Information on basic physical and chemical properties

Physical state:	clear solution
Appearance:	liquid
Color:	colorless to slightly reddish
Odor:	No data available
Odor threshold:	No data available
pH:	pH 3.0 – 4.0
Melting point:	No data available
Freezing point:	No data available
Boiling point:	No data available
Flash point:	Not applicable
Relative evaporation rate (butyl acetate=1):	No data available
Flammability (solid, gas):	Not applicable
Vapor pressure:	No data available
Relative vapor density at 20 °C:	No data available
Absolut density:	0.9900 – 1.0100 g/cm3
Solubility:	Solution
Partition coefficient n-octanol/water (Log Pow):	No data available
Auto-ignition temperature:	No data available
Decomposition temperature:	No data available
Viscosity, kinematic:	No data available
Viscosity, dynamic:	No data available
Explosion limits:	Not applicable
Explosive properties:	No data available
Oxidizing properties:	No data available

9.2. Other information
Not available.

SECTION 10: STABILITY AND REACTIVITY

10.1. Reactivity
The product is stable under normal conditions.

10.2. Chemical stability
The product is stable at handling and recommended storage conditions.

10.3. Possibility of hazardous reactions
No data available

10.4. Conditions to avoid
No data available

10.5. Incompatible materials
No data available

10.6. Hazardous decomposition products
If heated at high temperatures, the substance/mixture decomposes.

SECTION 11: TOXICOLOGICAL INFORMATION

11.1. Information on toxicological effects

Acute toxicity:

Physostigmine salicylate:	
LD50 (oral), rat:	7-10 mg/kg
Sodium metabisulfite:	
LD50 (oral), rat:	1540 mg/kg
LC50 (inhalation), rat:	> 5.5 mg/l/4h
LD50 (dermal), rat:	> 2000 mg/kg
Sodium edetate:	
LD50 (oral), rat:	> 2000 mg/kg

Potential Chronic Toxicity
Germ Cell Mutagenicity: No data
Carcinogenicity: No data
Reproductive Toxicity: No data.
Developmental: No data
Specific Target Organ Toxicity (Single Exposure): No data
Specific Target Organ Toxicity (Repeated Exposure): No data
Aspiration Hazard: No data

Toxicity studies with single administration have shown that the average lethal dose in rats is 1.28 mg/kg bodyweight after intramuscular administration, in rabbits it is 1.57 mg/kg bodyweight. An average lethal dose of 310 µg/kg bodyweight in mice and of 910 µg/kg bodyweight in rabbits has been determined after intravenous administration. Death occurred after unconsciousness and respiratory arrest.

Pregnancy: No data.

Physostigmine, the active substance contained in ANTICHOLIUM®, passes into the placenta. Animal studies are insufficient with respect to effects on pregnancy, embryonal/foetal development, birth and postnatal development. The potential risk for humans is unknown.

Breast-feeding: No data

11.2. Additionnal information

Due to the sodium metabisulfite content, hypersensitivity reactions may occur in isolatedcases, especially in asthmatics, which can manifest as retching, diarrhoea, wheezing, acute asthma attack, impaired consciousness or shock. These reactions can vary greatly between individuals and can also lead to life-threatening conditions. Under such conditions, a benefit-risk assessment is required when using ANTICHOLIUM® as an antidote in poisoning and a cortisone preparation must be readily available. Acute cardiac arrest is possible during treatment with tricyclic antidepressants, therefore continuous monitoring of the ECG is required when Anticholium is used as an antidote in this indication.

SECTION 12: ECOLOGICAL INFORMATION

12.1. Toxicity

No data available.

12.2. Persistence and degradability

No data available.

12.3. Bioaccumulative potential
No data available.

12.4. Mobility in soil
No data available.

12.5. Other adverse effects
No data available.

SECTION 13: DISPOSAL CONSIDERATIONS

13.1. Waste treatment methods
Advice on disposal: Dispose of waste in accordance with all applicable federal, state and local laws.
Waste disposal number of waste from residues/unused products : Dispose of waste in accordance with federal, state and local environment control regulations.
Contaminated packaging: Empty containers should be taken for local waste disposal. Contaminated packaging should be emptied as far as possible. Packaging that cannot be cleaned should be disposed of like the product.

SECTION 14: TRANSPORT INFORMATION

Pharmaceutical Waste : Physostigmine salicylate P1888
UN Number: 1851*
UN Proper Shipping Name: Medicine, liquid, toxic, n.o.s.*
Transport Hazard Class(es): Class 6.1 – poisonous material.*
Packing Group: PGII*
***Information for Physostigmine salicylate diluted at 0.1%

SECTION 15: REGULATORY INFORMATION

15.1. US Federal Regulations
U.S. Regulations:
Toxic Substance Control Act (TSCA): Yes
CERCLA Hazardous Substance: Physostigmine Salicylate (CAS 57-64-7) Listed
EPCRA Extremely Hazardous Substances and Toxic Chemicals:

Ingredient	Section 302	Section 313
physostigmine salicylate (CAS 57-64-7)	100/10,000 lbs	No

15.2. U.S. STATE RIGHT-TO-KNOW REGULATIONS

Ingredient	New jersey	Pennsylvania	Massachussets	California Proposition 65
physostigmine salicylate (CAS 57-64-7)	Listed	Listed	Listed	Not listed

15.3. ECHA Status
EU – Regulations
No REACH Annex XVII restrictions
Anticholium® is not on the REACH Candidate List
Anticholium® is not on the REACH Annex XIV List
No hazardous substance in the sense of the EC directives / GefStoffV.

SECTION 16: OTHER INFORMATION

Anticholium® (German imported product)
At this time, no other entity except Provepharm or its distributor Direct Success is authorized by the FDA to import or distribute physostigmine salicylate injection in the U.S.
Effective immediately, Provepharm will distribute the following presentations of Anticholium® (physostigmine salicylate) to address the critical shortage:

Product Description	Strength	Packaging	NDC number	Lot/ Batch #	Expiration Date (Labeled)
Anticholium® (physostigmine salicylate)	2 mg/5 mL (0.4 mg/mL) injection for intravenous use	5 x 5 mL ampules	81284-831-05	2315751	2026-05-31

Full text of H-phrases:

Acute Tox 1	Acute toxicity (Category 1)
Acute Tox 2	Acute toxicity (Category 2)
Acute Tox. 4	Acute toxicity (Category 4)
Eye Dam. 1	Eye damage (Category 1)
STOT RE 2	Specific target organ toxicity - repeated exposure, category 2
H300	Fatal if swallowed
H330	Fatal if inhaled
H302	Harmful if swallowed
H318	Causes serious eye damage
H332	Harmful if inhaled
H373	May cause damage to organs through prolonged or repeated exposure